Saudi Journal of Gastroenterology

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 21  |  Issue : 1  |  Page : 47--50

Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis


Mehmet Ulu1, Ahmet Alacacioglu2, Esma Yuksel3, Baris O Pamukk2, Giray Bozkaya1, Alpay Ari1, Arif Yuksel1, Gulten Sop1, Inci Alacacioglu4 
1 Bozyaka Training and Research Hospital, Izmir, Turkey
2 Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
3 Karsiyaka Government Hospital, Izmir, Turkey
4 Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey

Correspondence Address:
Mehmet Ulu
Izmir Katip Celebi University, Ataturk Training and Research Hospital, Medical Oncology Clinic, 35360-Izmir
Turkey

Background/Aim: Galectins affect diverse physiological and pathophysiological processes such as development, inflammation, and tumor growth. We aimed to compare serum galectin-3 levels in three patient groups with chronic hepatitis B and C virus (HBV, HCV), cirrhosis secondary to HBV or HCV, and hepatocellular carcinoma (HCC) secondary to HBV or HCV and evaluate the role of galectin-3 during HCC progression. Patients and Methods: Nineteen patients with hepatocellular cancer, 22 patients with cirrhosis, and 24 patients with chronic hepatitis B and C were included in this study. Serum galectin-3 levels in different liver diseases were assessed by enzyme-linked immunosorbent assay. Results: The mean galectin-3 levels were 4.61 ng/mL (±2.32) in HCC patients, 5.68 ng/mL (±2,2) in cirrhotic patients, 1.98 ng/mL (±1.50) in chronic viral hepatitis group. There were no statistical differences between HCC and cirrhotic patients (P = 0.5), but lower in chronic hepatitis group statistically compared with cirrhosis and HCC (P < 0.001, P = 0.002, respectively). In case of cirrhotic patients, galectin-3 levels were significantly higher in patients with cirrhosis secondary to HCV compared with HBV (P = 0.03). When we evaluated galectin-3 levels in HCC patients, it was found to be 3.92 ng/mL in HCC secondary to hepatitis B and 5.37 ng/mL in HCC secondary to hepatitis C. Conclusion: Serum galectin-3 levels in patients with chronic HBV or HCV may guide us about progression to cirrhosis or HCC and prognosis of the disease. Especially, galectin-3 levels may be more pronounced in case of HCV.


How to cite this article:
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G, Alacacioglu I. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.Saudi J Gastroenterol 2015;21:47-50


How to cite this URL:
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A, Yuksel A, Sop G, Alacacioglu I. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol [serial online] 2015 [cited 2021 Dec 7 ];21:47-50
Available from: https://www.saudijgastro.com/article.asp?issn=1319-3767;year=2015;volume=21;issue=1;spage=47;epage=50;aulast=Ulu;type=0